Raymond James Upgrades Oncolytics Biotech (NASDAQ:ONCY) to Moderate Buy

Raymond James upgraded shares of Oncolytics Biotech (NASDAQ:ONCY) to a moderate buy rating in a research note issued to investors on Thursday,Zacks.com reports. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.

Several other research analysts have also recently issued reports on the company. Leede Financial cut Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research report on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Oncolytics Biotech in a report on Thursday.

Oncolytics Biotech Price Performance

ONCY stock opened at $0.98 on Thursday. The business’s 50-day moving average is $1.09 and its two-hundred day moving average is $1.05. Oncolytics Biotech has a 1 year low of $0.84 and a 1 year high of $1.75. The firm has a market capitalization of $75.53 million, a P/E ratio of -3.63 and a beta of 1.69.

Institutional Trading of Oncolytics Biotech

An institutional investor recently bought a new position in Oncolytics Biotech stock. Virtu Financial LLC acquired a new stake in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 0.07% of Oncolytics Biotech as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.